{"id":713,"date":"2021-07-22T00:18:17","date_gmt":"2021-07-22T04:18:17","guid":{"rendered":"https:\/\/pressbooks.bccampus.ca\/rickyturgeon\/?post_type=chapter&p=713"},"modified":"2024-03-14T16:02:14","modified_gmt":"2024-03-14T20:02:14","slug":"general-considerations","status":"publish","type":"chapter","link":"https:\/\/pressbooks.bccampus.ca\/rickyturgeon\/chapter\/general-considerations\/","title":{"raw":"Do the results (not) apply to my patients?","rendered":"Do the results (not) apply to my patients?"},"content":{"raw":"[pb_glossary id=\"1653\"]Generalizability[\/pb_glossary] is often understood in terms of [pb_glossary id=\"323\"]PICO[\/pb_glossary], which is an acronym for \"patient, intervention, comparator, and outcome\". These are the four basic elements of a study. For instance, a study may examine an elderly population (P) to understand the effects of statin therapy (I) compared to placebo\u00a0(C) in terms of cardiovascular events (O). The following questions are intended to comprehensively address each of these elements.\r\n\r\nMost considerations of [pb_glossary id=\"1653\"]generalizability[\/pb_glossary] are independent of study type. So, unless explicitly noted otherwise, the following questions are applicable to both [pb_glossary id=\"704\"]randomized controlled trials[\/pb_glossary] and [pb_glossary id=\"1099\"]systematic reviews[\/pb_glossary]\/[pb_glossary id=\"1101\"]meta-analyses[\/pb_glossary].\r\n

Checklist Questions<\/h1>\r\n
\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
How does my practice setting differ from that in the trials?<\/td>\r\n<\/tr>\r\n
How do my patients differ from those included in the trial?<\/td>\r\n<\/tr>\r\n
How do the trial interventions differ from those available in my practice?<\/td>\r\n<\/tr>\r\n
Are the trial outcomes clinically important?<\/td>\r\n<\/tr>\r\n
Does the trial reflect my patients' risk of adverse events? What differences exist?<\/td>\r\n<\/tr>\r\n
[[pb_glossary id=\"704\"]Randomized controlled trials[\/pb_glossary] only] Did the study design have a pre-randomization [pb_glossary id=\"308\"]run-in period[\/pb_glossary]?<\/td>\r\n<\/tr>\r\n
[[pb_glossary id=\"1099\"]Systematic reviews[\/pb_glossary]\/[pb_glossary id=\"1101\"]meta-analyses[\/pb_glossary] only] Was each element of [pb_glossary id=\"323\"]PICO[\/pb_glossary] (i.e. patient, intervention, comparator, and outcome) sufficiently reported to assess [pb_glossary id=\"1653\"]generalizability[\/pb_glossary]?<\/td>\r\n<\/tr>\r\n
Do the differences above impede the [pb_glossary id=\"1653\"]generalizability[\/pb_glossary] of the study findings to my practice?<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/div>\r\n

Does my practice setting differ from that in the trials?<\/h1>\r\nSetting considerations:\r\n